Biogen Is Dropping Controversial Alzheimer’s Drug Aduhelm
WEDNESDAY, Jan. 31, 2024 (HealthDay News) — Biogen, maker of the Alzheimer’s medicine Aduhelm, announced Wednesday that it would “discontinue the development and commercialization” of the controversial drug. Biogen will return the rights to Aduhelm to Neurimmune, the private firm that invented it, the company said in a statement. It’sContinue Reading